Select a medication above to begin.
L-gamma-glutamyl-L-cystéinyl-glycine
glutathione
Entire Monograph
Reported Uses
- NOTE: see Herb & Supplement Effectiveness Rating Definitions table
- aging [Insufficient Evidence]
- alcohol withdrawal sx [Insufficient Evidence]
- Alzheimer dz [Insufficient Evidence]
- angioplasty [Insufficient Evidence]
- athletic performance [Insufficient Evidence]
- cardiovascular dz prevention [Insufficient Evidence]
- cataracts [Insufficient Evidence]
- chronic fatigue syndrome [Insufficient Evidence]
- cirrhosis [Insufficient Evidence]
- cognitive function [Insufficient Evidence]
- cystic fibrosis [Insufficient Evidence]
- glaucoma [Insufficient Evidence]
- idiopathic interstitial pneumonia [Insufficient Evidence]
- nephropathy, contrast-induced [Insufficient Evidence]
- neurotoxicity, cisplatin-induced [Possibly Effective]
- nonalcoholic fatty liver dz [Insufficient Evidence]
- osteoarthritis [Insufficient Evidence]
- Parkinson dz [Insufficient Evidence]
Reported Doses
Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies w/ variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely
Effectiveness Ratings
- [see Herb & Supplement Effectiveness Rating Definitions table]
angioplasty
- [Insufficient Evidence]
- Dose: 2.5 g/25 mL IV x1 before procedure, then 2.5 g/25 mL IV x1 given at 24h, 48h, 72h after procedure; Info: product containing glutathione sodium
athletic performance
- [Insufficient Evidence]
- Dose: 200 mg PO qd
neurotoxicity, cisplatin-induced
- [Possibly Effective]
- Dose: 1.5-3 g/m^2/dose IV x1 before chemo; Alt: 1.5 g/m^2/dose IV x1 before chemo plus 600 mg IM qd on days 2-5
nonalcoholic fatty liver dz
- [Insufficient Evidence]
- Dose: 300 mg PO qd
Copyright © 2024. All Rights Reserved. Republication or redistribution, including by framing or similar means, is prohibited without the prior written consent of copyright holder.